Department of Neurology, The Royal Children's Hospital, Melbourne, Australia; Murdoch Children's Research Institute, Melbourne, Australia; Department of Physiotherapy, The University of Melbourne, Australia.
Department of Physiotherapy, The University of Melbourne, Australia.
Neuromuscul Disord. 2021 Aug;31(8):706-715. doi: 10.1016/j.nmd.2021.05.011. Epub 2021 Jun 1.
This study aims to investigate intra-rater reliability and construct validity of the Facioscapulohumeral Dystrophy Composite Outcome Measure (FSHD-COM), in childhood FSHD. Participants included eighteen children with FSHD, and matched healthy controls. Reliability data were collected from 15 participants with FSHD over two testing sessions. Validity data were collected from all participants. Participants with FSHD completed; the FSHD-COM (and modified pediatric version), Motor Function Measure-32 (MFM-32), FSHD Severity Scales, Performance of the Upper Limb 2.0, Pediatric Quality of Life™ Neuromuscular Module and pediatric FSHD Health-Index Questionnaire. Both versions of the FSHD-COM showed excellent intra-rater reliability (ICC > 0.99, lower 95%CI > 0.98) with a Minimal Detectable Change (MDC95%) of ≤14.5%. The FSHD-COM had robust and widespread correlations with other related outcome measures. The FSHD-COM versions and 6 min walk test effectively discriminated between children with and without FSHD; the MFM-32 and 10 m walk/run test did not. Ceiling effects were not observed on either version of the FSHD-COM. Reliability and validity findings in this childhood FSHD study concord with estimates in adults. Both versions of the FSHD-COM were effective in discriminating disease in children with mild FSHD symptoms. The FSHD-COM has the potential to be a useful measure of function across the life span.
本研究旨在探讨面肩肱型肌营养不良症综合评定量表(FSHD-COM)在儿童期 FSHD 中的内部信度和结构效度。参与者包括 18 名 FSHD 患儿和匹配的健康对照组。信度数据来自 15 名 FSHD 患儿的两次测试。所有参与者均收集了有效性数据。FSHD 患儿完成了 FSHD-COM(和改良儿科版)、运动功能测量-32 量表(MFM-32)、FSHD 严重程度量表、上肢功能 2.0 测试、儿科生活质量™神经肌肉模块和儿科 FSHD 健康指数问卷。FSHD-COM 的两个版本均表现出极好的内部信度(ICC > 0.99,下限 95%CI > 0.98),最小可检测变化(MDC95%)≤14.5%。FSHD-COM 与其他相关结局测量指标具有广泛而有力的相关性。FSHD-COM 版本和 6 分钟步行测试有效地区分了有无 FSHD 的患儿;MFM-32 和 10 米步行/跑测试则不能。FSHD-COM 的两个版本均未观察到天花板效应。本儿童期 FSHD 研究中的信度和效度发现与成人的估计值一致。FSHD-COM 的两个版本在区分轻度 FSHD 症状患儿的疾病方面均有效。FSHD-COM 有可能成为一种有用的生命全程功能评估工具。